Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, In-Patient Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

NCT06107803 is registered in ClinicalTrials.gov with Minerva Neurosciences as lead sponsor.

NCT NCT06107803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06107803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, In-Patient Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
Lead sponsor
Minerva Neurosciences
Phase
Phase 1
Overall status
Completed
Start date
October 13, 2023
Completion date
January 12, 2024
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

negative symptoms in schizophrenia